Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Takafumi Sakuma"'
Autor:
Sae Yumita, Sadahisa Ogasawara, Miyuki Nakagawa, Susumu Maruta, Tomomi Okubo, Norio Itokawa, Yotaro Iino, Masamichi Obu, Yuki Haga, Atsuyoshi Seki, Tadayoshi Kogure, Takamasa Ishino, Keita Ogawa, Kisako Fujiwara, Terunao Iwanaga, Naoto Fujita, Takafumi Sakuma, Ryuta Kojima, Hiroaki Kanzaki, Keisuke Koroki, Masanori Inoue, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Takayuki Kondo, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Ei Itobayashi, Masanori Atsukawa, Yoshihiro Koma, Ryosaku Azemoto, Kenji Ito, Hideaki Mizumoto, Jun Kato, Naoya Kato
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Hyperprogressive disease (HPD) is a phenomenon with greatly accelerated tumor growth and clinical deterioration rates compared to pre-therapy, in patients treated with immune checkpoint inhibitors (ICI). The aim of this study is t
Externí odkaz:
https://doaj.org/article/e6438030eab2449d8f1c4414595c6e53
Autor:
Naoya Kanogawa, Sadahisa Ogasawara, Susumu Maruta, Yotaro Iino, Masamichi Obu, Takamasa Ishino, Keita Ogawa, Sae Yumita, Terunao Iwanaga, Hidemi Unozawa, Miyuki Nakagawa, Kisako Fujiwara, Takafumi Sakuma, Naoto Fujita, Ryuta Kojima, Hiroaki Kanzaki, Keisuke Koroki, Kazufumi Kobayashi, Masanori Inoue, Soichiro Kiyono, Masato Nakamura, Takayuki Kondo, Tomoko Saito, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Ei Itobayashi, Yoshihiro Koma, Ryosaku Azemoto, Jun Kato, Naoya Kato
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Purpose Ramucirumab was shown to be effective as a second-line treatment after sorafenib in patients with advanced hepatocellular carcinoma (HCC) with alpha-fetoprotein levels > 400 ng/mL in a worldwide phase 3 trial. Ramucirumab is used in
Externí odkaz:
https://doaj.org/article/ec4cc9154a2f40df8dcaa61493fe4d89
Autor:
Takayuki Kondo, Kisako Fujiwara, Miyuki Nakagawa, Hidemi Unozawa, Terunao Iwanaga, Takafumi Sakuma, Naoto Fujita, Keisuke Koroki, Hiroaki Kanzaki, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Sadahisa Ogasawara, Eiichiro Suzuki, Yoshihiko Ooka, Shingo Nakamoto, Tetsuhiro Chiba, Makoto Arai, Jun Kato, Naoya Kato
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract The screening of gastroesophageal varices (GEV) is critical in hepatocellular carcinoma (HCC) management. Contrast-enhanced computed tomography (CECT) is often performed in patients with HCC. Therefore, this study aimed to examine the use of
Externí odkaz:
https://doaj.org/article/195628a7649a45c4815c5e21e0540138
Autor:
Shogo Watari, Takaharu Ichikawa, Hiromasa Shiraishi, Takafumi Sakuma, Risa Kubota, Norihiro Kusumi, Tomoyasu Tsushima, Keina Nagakita, Yoko Shinno
Publikováno v:
IJU Case Reports, Vol 5, Iss 5, Pp 378-382 (2022)
Introduction Extramammary myofibroblastomas are extremely rare. Case presentation The patient was an 88‐year‐old male. He presented for evaluation of frequent urination and a “pushing up” sensation from the groin during defecation. Thorough p
Externí odkaz:
https://doaj.org/article/f999f6a26ec84222ac222de7a28d2b2e
Autor:
Kazufumi Kobayashi, Sadahisa Ogasawara, Aya Takahashi, Yuya Seko, Hidemi Unozawa, Rui Sato, Shunji Watanabe, Michihisa Moriguchi, Naoki Morimoto, Satoshi Tsuchiya, Kenji Iwai, Masanori Inoue, Keita Ogawa, Takamasa Ishino, Terunao Iwanaga, Takafumi Sakuma, Naoto Fujita, Hiroaki Kanzaki, Keisuke Koroki, Masato Nakamura, Naoya Kanogawa, Soichiro Kiyono, Takayuki Kondo, Tomoko Saito, Ryo Nakagawa, Eiichiro Suzuki, Yoshihiko Ooka, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Tatsuo Kanda, Hitoshi Maruyama, Kengo Nagashima, Jun Kato, Norio Isoda, Takeshi Aramaki, Yoshito Itoh, Naoya Kato
Publikováno v:
Liver Cancer, Pp 1-13 (2021)
Background and Aims: The prognosis of patients with advanced hepatocellular carcinoma (HCC) is expected to improve as multiple molecular target agents (MTAs) are now available. However, the impact of the availability of sequential MTAs has not been f
Externí odkaz:
https://doaj.org/article/3d27bd60476f43d0ad39fa2137391db5
Autor:
Shohei Mukai, Hiroaki Kanzaki, Sadahisa Ogasawara, Takamasa Ishino, Keita Ogawa, Miyuki Nakagawa, Kisako Fujiwara, Hidemi Unozawa, Terunao Iwanaga, Takafumi Sakuma, Naoto Fujita, Keisuke Koroki, Kazufumi Kobayashi, Naoya Kanogawa, Soichiro Kiyono, Masato Nakamura, Takayuki Kondo, Tomoko Saito, Ryo Nakagawa, Eiichiro Suzuki, Yoshihiko Ooka, Ryosuke Muroyama, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Jun Kato, Manayu Shiina, Masayuki Ota, Jun‐ichiro Ikeda, Yuichi Takiguchi, Masayuki Ohtsuka, Naoya Kato
Publikováno v:
JGH Open, Vol 5, Iss 11, Pp 1266-1274 (2021)
Abstract Background and Aim Immune checkpoint inhibitors and their combination with other agents have recently been available in advanced hepatocellular carcinoma (HCC). Hence, a thorough understanding of the tumor microenvironment based on tumor sam
Externí odkaz:
https://doaj.org/article/e082e4c91a2142358c016fb7ff695a59
Autor:
Ryoi Yoshida, Keisuke Koroki, Hirokazu Makishima, Sadahisa Ogasawara, Takamasa Ishino, Keita Ogawa, Miyuki Nakagawa, Kisako Fujiwara, Hidemi Unozawa, Terunao Iwanaga, Naoto Fujita, Takafumi Sakuma, Hiroaki Kanzaki, Kazufumi Kobayashi, Naoya Kanogawa, Soichiro Kiyono, Masato Nakamura, Takayuki Kondo, Tomoko Saito, Ryo Nakagawa, Eiichiro Suzuki, Yoshihiko Ooka, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Takashi Kaneko, Masaru Wakatsuki, Jun Kato, Hiroshi Tsuji, Naoya Kato
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 2, Pp 1103-1110 (2021)
Macrovascular invasion (MVI), including portal vein tumor thrombosis (PVTT), is strongly associated with poor prognosis in patients with hepatocellular carcinoma (HCC). While recommended standard treatment for patients with advanced HCC is systemic t
Externí odkaz:
https://doaj.org/article/a26491db54d54c3589460f579d52e795
Autor:
Keisuke Koroki, Naoya Kanogawa, Susumu Maruta, Sadahisa Ogasawara, Yotaro Iino, Masamichi Obu, Tomomi Okubo, Norio Itokawa, Takahiro Maeda, Masanori Inoue, Yuki Haga, Atsuyoshi Seki, Shinichiro Okabe, Yoshihiro Koma, Ryosaku Azemoto, Masanori Atsukawa, Ei Itobayashi, Kenji Ito, Nobuyuki Sugiura, Hideaki Mizumoto, Hidemi Unozawa, Terunao Iwanaga, Takafumi Sakuma, Naoto Fujita, Hiroaki Kanzaki, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Tomoko Saito, Takayuki Kondo, Eiichiro Suzuki, Yoshihiko Ooka, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Tatsuo Kanda, Hitoshi Maruyama, Jun Kato, Naoya Kato
Publikováno v:
Liver Cancer, Pp 1-12 (2021)
Background: There is no standard posttreatment for patients with advanced hepatocellular carcinoma (HCC) in whom lenvatinib therapy has failed. This study aimed to investigate rates of migration to posttreatment after lenvatinib and to explore candid
Externí odkaz:
https://doaj.org/article/4cc7f3182bb149d4bf42ff53cc56445b
Autor:
Naoya Kanogawa, Sadahisa Ogasawara, Yoshihiko Ooka, Masanori Inoue, Toru Wakamatsu, Masayuki Yokoyama, Susumu Maruta, Hidemi Unozawa, Terunao Iwanaga, Takafumi Sakuma, Naoto Fujita, Keisuke Koroki, Hiroaki Kanzaki, Takahiro Maeda, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Takayuki Kondo, Tomoko Saito, Tenyu Motoyama, Eiichiro Suzuki, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Tatsuo Kanda, Hitoshi Maruyama, Jun Kato, Ryo Takemura, Natsuko Nozaki‐Taguchi, Isono Shiroh, Osamu Yokosuka, Naoya Kato
Publikováno v:
JGH Open, Vol 5, Iss 2, Pp 273-279 (2021)
Abstract Background and Aim Standardization of the sedation protocol during radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC) is needed. This randomized, single‐blind, investigator‐initiated trial compared clinical out
Externí odkaz:
https://doaj.org/article/7f27397a7ce3413e8772f8b1cbb15834
Autor:
Masato Nakamura, Takayuki Kondo, Yohei Kawasaki, Hideki Hanaoka, Naoya Kato, Sadahisa Ogasawara, Keisuke Koroki, Hirokazu Makishima, Masaru Wakatsuki, Asahi Takahashi, Sae Yumita, Miyuki Nakagawa, Takamasa Ishino, Keita Ogawa, Kisako Fujiwara, Terunao Iwanaga, Takafumi Sakuma, Naoto Fujita, Ryuta Kojima, Hiroaki Kanzaki, Kazufumi Kobayashi, Soichiro Kiyono, Naoya Kanogawa, Tomoko Saito, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Yoshihito Ozawa, Tomoya Kurokawa, Hiroshi Tsuji
Publikováno v:
BMJ Open, Vol 12, Iss 4 (2022)
Introduction Advanced hepatocellular carcinoma (HCC) with macrovascular invasion (MVI) has the worst prognosis among all phenotypes. This trial aims to evaluate whether treatment with durvalumab, alone or in combination with tremelimumab, plus partic
Externí odkaz:
https://doaj.org/article/10cba6c799024b70a6436dd19587d4d4